121 related articles for article (PubMed ID: 15823792)
21. Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells.
Kopera D; Hohenleutner U; Stolz W; Landthaler M
Dermatology; 1997; 194(4):344-50. PubMed ID: 9252755
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
23. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
24. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
[TBL] [Abstract][Full Text] [Related]
25. Expression of p-27 (kip1) in nevi and melanomas.
Morgan MB; Cowper SE
Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670
[TBL] [Abstract][Full Text] [Related]
26. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
27. Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas.
Ieni A; Barresi V; Branca G; Giuffrè G; Rosa MA; Tuccari G
Oncol Lett; 2013 May; 5(5):1536-1540. PubMed ID: 23761817
[TBL] [Abstract][Full Text] [Related]
28. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
29. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
30. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
Krengel S; Grotelüschen F; Bartsch S; Tronnier M
J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
[TBL] [Abstract][Full Text] [Related]
31. Dermatoscopy versus Tzanck smear test: a comparison of the value of two tests in the diagnosis of pigmented skin lesions.
Durdu M; Baba M; Seçkin D
J Am Acad Dermatol; 2011 Nov; 65(5):972-82. PubMed ID: 21565420
[TBL] [Abstract][Full Text] [Related]
32. Fixed-tissue binding of fluorescein-conjugated concanavalin A to malignant melanomas versus nevi.
Miller A; Barr RJ
J Am Acad Dermatol; 1984 Oct; 11(4 Pt 1):620-4. PubMed ID: 6490986
[TBL] [Abstract][Full Text] [Related]
33. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
34. IMP-3 expression in melanocytic lesions.
Yu L; Xu H; Wasco MJ; Bourne PA; Ma L
J Cutan Pathol; 2010 Mar; 37(3):316-22. PubMed ID: 19788446
[TBL] [Abstract][Full Text] [Related]
35. JARID1B expression in human melanoma and benign melanocytic skin lesions.
Kuźbicki L; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2013 Feb; 23(1):8-12. PubMed ID: 23262439
[TBL] [Abstract][Full Text] [Related]
36. Immunolocalization of lactoferrin in cartilage-forming neoplasms.
Ieni A; Barresi V; Grosso M; Rosa MA; Tuccari G
J Orthop Sci; 2009 Nov; 14(6):732-7. PubMed ID: 19997820
[TBL] [Abstract][Full Text] [Related]
37. Meyerson Phenomenon as a Component of Melanoma in situ.
Sezer E; Özturk Durmaz E; Çetin E; Şahin S
Acta Dermatovenerol Croat; 2016 Apr; 24(1):81-2. PubMed ID: 27149137
[TBL] [Abstract][Full Text] [Related]
38. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
39. [Use of curettage in the treatment of skin tumors].
Jensen P
Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3245-6. PubMed ID: 9411867
[TBL] [Abstract][Full Text] [Related]
40. Multicellular origin of tenascin in skin tumors--an in situ hybridization study.
Tuominen H; Pöllänen R; Kallioinen M
J Cutan Pathol; 1997 Nov; 24(10):590-6. PubMed ID: 9449485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
